SLC30A6: A Potential Drug Target and Biomarker (G55676)

Target Name: SLC30A6

NCBI ID: G55676

SLC30A6

SLC30A6: A Potential Drug Target and Biomarker

Solute Carrier Family 30 (SLC30) is a family of transmembrane proteins that play a significant role in various physiological processes in the body. One of the members of this family is SLC30A6, which has been identified as a potential drug target and biomarker for various diseases. In this article, we will discuss the SLC30A6 protein, its function, potential drug targets, and its potential as a biomarker.

SLC30A6: Structure and Function

SLC30A6 is a member of the SLC30 family and has a molecular weight of approximately 120 kDa. It consists of a single transmembrane domain and a cytoplasmic tail. The transmembrane domain of SLC30A6 contains four putative ion channels, two of which are involved in the transport of amino acids and nucleotides across the membrane. The cytoplasmic tail of SLC30A6 contains a single glycophorin gene that encodes a protein with potential structural and functional roles in cell signaling.

SLC30A6 has been shown to play a role in various physiological processes, including cell signaling, neurotransmission, and intracellular signaling. For example, SLC30A6 has been shown to be involved in the regulation of neurotransmitter release from axons in the central nervous system, which is critical for various behaviors and neurotransactions. Additionally, SLC30A6 has been shown to play a role in the regulation of ion channels in various cell types, including muscle and epithelial cells.

Potential Drug Targets

SLC30A6 has been identified as a potential drug target for various diseases due to its involvement in various physiological processes. One of the potential drug targets for SLC30A6 is the regulation of neurotransmitter release from axons in the central nervous system. This is because neurotransmitter release is critical for the regulation of various behaviors and neurotransactions, and drugs that can modulate neurotransmitter release have been shown to have therapeutic benefits for various neurological and psychiatric disorders.

Another potential drug target for SLC30A6 is its role in the regulation of ion channels in various cell types. Ion channels play a critical role in the regulation of various physiological processes, including muscle and epithelial function. Drugs that can modulate ion channels have been shown to have therapeutic benefits for various diseases, including heart failure, hypertension, and cancer.

Potential Biomarkers

SLC30A6 has also been identified as a potential biomarker for various diseases due to its involvement in various physiological processes. One of the potential biomarkers for SLC30A6 is its role in the regulation of neurotransmitter release from axons in the central nervous system. This is because neurotransmitter release is a critical indicator of the function of the nervous system, and changes in neurotransmitter release have been shown to be associated with various neurological and psychiatric disorders.

Another potential biomarker for SLC30A6 is its role in the regulation of ion channels in various cell types. Ion channels play a critical role in the regulation of various physiological processes, and changes in ion channel function have been shown to be associated with various diseases, including heart failure, hypertension, and cancer.

Conclusion

SLC30A6 is a protein that has been shown to play a role in various physiological processes in the body. Its potential as a drug target and biomarker makes it an attractive target for research into the treatment of various diseases. Further studies are needed to fully understand the function of SLC30A6 and its potential as a drug

Protein Name: Solute Carrier Family 30 Member 6

Functions: Has probably no intrinsic transporter activity but together with SLC30A5 forms a functional zinc ion:proton antiporter heterodimer, mediating zinc entry into the lumen of organelles along the secretory pathway (PubMed:15994300, PubMed:19366695, PubMed:19759014). As part of that zinc ion:proton antiporter, contributes to zinc ion homeostasis within the early secretory pathway and regulates the activation and folding of enzymes like alkaline phosphatases and enzymes involved in phosphatidylinositol glycan anchor biosynthesis (PubMed:15994300, PubMed:19759014, PubMed:35525268)

The "SLC30A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC30A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets